Revenue from Contracts with Customers

6 Months Ended

Jun. 30, 2026

Revenue from Contracts with Customers

Revenue from Contracts with Customers

3.   Revenue from Contracts with Customers. We recognize revenue when a customer obtains control of promised goods. The amount of revenue recognized reflects the consideration we expect to receive in exchange for these goods. Our revenue recognition policies have not changed from those disclosed in Note 1 to our consolidated financial statements in Item 8 of the 2025 Annual Report on Form 10-K.

Disaggregation of Revenue

Our revenue is disaggregated based on product category, platform and geographic region. In addition to the change in segments, beginning in the first quarter of 2026, we adjusted our product categories and platforms to better reflect the clinical uses of our products. As a result of these changes, our revenue categories have been recast for the historical periods presented.

We design, develop, manufacture and market medical products for interventional, diagnostic and therapeutic procedures. For financial reporting purposes, we report our operations as a single operating segment with two product categories: foundational and therapeutic. Foundational products are used primarily for access and enabling functions in vascular and other procedures, and include product platforms such as access devices, procedural solutions, original equipment manufacturer (“OEM”) products, and vascular intervention. Therapeutic products are devices and systems used to treat a broad array of diseases, and include product platforms such as cardiac therapies, oncology, renal therapies, vascular intervention, OEM products and endoscopy.

The following table presents revenue from contracts with customers by product category and platform for the three and six-month periods ended June 30, 2026 and 2025 (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2026		2025		2026		2025
Foundational
Access	$	161,786	$	152,122	$	312,910	$	286,520
OEM		48,338		43,218		87,878		86,641
Procedural Solutions		27,949		31,741		54,437		60,310
Vascular Intervention		41,652		34,955		80,690		67,804
Other		1,236		346		525		1,489
Total Foundational		280,961		262,382		536,440		502,764
Therapeutic
Cardiac Therapies		28,510		22,930		55,914		43,489
Endoscopy		23,647		18,400		45,339		34,951
OEM		12,797		9,735		20,276		20,877
Oncology		25,774		23,943		49,282		45,994
Renal Therapies		12,713		12,817		24,225		26,206
Vascular Intervention		34,441		32,255		69,244		63,532
Total Therapeutic		137,882		120,080		264,280		235,049
Total	$	418,843	$	382,462	$	800,720	$	737,813

The following table presents revenue from contracts with customers by geographic region for the the three and six-month periods ended June 30, 2026 and 2025 (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2026		2025		2026		2025
Domestic	$	252,051	$	227,082	$	478,567	$	440,646
International		166,792		155,380		322,153		297,167
Total	$	418,843	$	382,462	$	800,720	$	737,813